Gastric Cancer

P=N/A, N=2000, Not yet recruiting, LanZhou University | Initiation date: Jan 2026 --> Jul 2026

P2, N=54, Completed, Hospices Civils de Lyon | Unknown status --> Completed | Trial completion date: Oct 2023 --> Jun 2026 | Trial primary completion date: Oct 2023 --> Jun 2026

Furthermore, we will briefly discuss endoscopic treatment, chemotherapy, and surgical treatment for GEJ cancer. Looking ahead, the reclassification of GEJ cancers using the Kyoto international consensus, coupled with comprehensive molecular analyses of tumors, promises to yield valuable insights.

SIRT3 promotes GC progression and chemoresistance by deacetylating and stabilizing the mitochondrial ADP/ATP translocator SLC25A6 (ANT3), thereby enhancing mitochondrial metabolic activity. The SIRT3-ANT3 axis represents a novel molecular mechanism driving GC malignancy and chemoresistance and may serve as a promising therapeutic target for improving treatment efficacy in GC.

Moreover, ALS2 was required for H. pylori-induced Rab5 activation, early endosome enlargement, and downstream β-catenin signaling, as shown by shRNA-mediated knockdown of endogenous ALS2. Taken together, these observations uncover a novel pathway induced by H. pylori in gastric cells, which involves the HIF-1α/ALS2/Rab5/β-catenin signaling axis.

FTO suppresses BCL6 via m6 A demethylation, inhibiting ferroptosis to promote GC progression. The FTO/BCL6 axis is a potential therapeutic target for GC.

Elevated RIPK4 expression in plasma-derived cfRNA and tumor tissue was associated with a poor response to nivolumab, suggesting that RIPK4 may serve as a biomarker of ICI efficacy in gastric cancer. Further studies are warranted to validate its clinical utility.

P=N/A, N=96, Recruiting, Tang-Du Hospital | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027

P=N/A, N=52, Recruiting, Qilu Hospital of Shandong University

P1, N=83, Active, not recruiting, HiFiBiO Therapeutics | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P=N/A, N=76, Not yet recruiting, Chinese University of Hong Kong

HIMT is rare and poses significant diagnostic challenges that often mimic other liver malignancies. This case report highlights the efficacy and safety of laparoscopic hepatectomy as both a diagnostic and therapeutic strategies.